CARDIO DIAGNOSTICS HOLDINGS INC (CDIO)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.86+1.64%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · CDIO
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -1.5% |
| Our one-year growth estimate | diamond | 87.6% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 89.1 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name has been missing across recent quarters and is a smaller-cap name (higher miss base rate). A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 399 industry peers · Company calendar date is not available
CDIO — litigation filed
Dated 2026-02-19
Regulation FD Disclosure. On February 19, 2026, Cardio Diagnostics Holdings, Inc. (the “Company”) is holding an investor conference call (the “Investor Call”) at 3 p.m. Central Standard Time to discuss the Company’s current status, recent developments, and ongoing strategic priorities. During the Investor Call, members of the Company’s management are discussing, among other things: · Corporate updates and recent developments; · Recent clinical data; · Reimbursement progress; and · Strategic i…
Why it matters: Any updates on financial goals could signal a shift in strategy. This affects how investors view the company.
Watch forManagement gives a more positive view on revenue or profit.
Also watch forManagement cuts their forecast. They also show concerns about future results.
Why it matters: Steady revenue growth shows that more people are using Cardio Diagnostics' tests and services.
Supportive ifRevenue growth reported above $5.36M in the next quarterly results.
Worry ifRevenue declines or stagnates below the current level of $5.36M.
Why it matters: Management's strategy can show how the company will do in the future. Good changes may lead to better money results.
Supportive ifManagement has a new plan to cut losses.
Worry ifManagement is still using the same plan with no new ideas.
Why it matters: The earnings report will provide insights into financial health and future guidance. This is critical for assessing performance.
Watch forThe earnings report shows a profit. Revenue is better than expected.
Also watch forThe earnings report shows a bigger loss. Revenue is worse than expected.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$302 on $10,000 · ±3.0% | How much price usually moves either way. |
| Bad day | $1,076 loss on $10,000 · 10.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $7,908 loss on $10,000 · 79.1% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: If healthcare sector revenue growth speeds up, it may help Cardio Diagnostics. This could improve investor sentiment.
Supportive ifHealthcare sector revenue growth rises above 10% year over year.
Worry ifHealthcare sector revenue growth remains below 9% year over year.
Why it matters: Cutting costs can help Cardio Diagnostics make more money and work better.
Supportive ifNews about more cost cuts in lab processing beyond the first 30%.
Worry ifNo further reductions in lab costs or an increase in cost of goods sold.
Why it matters: Steady revenue growth shows good market use and business growth.
Supportive ifQuarterly revenue growth is over 20% compared to last quarter.
Worry ifQuarterly revenue growth falls below 10% or turns negative.
Why it matters: A drop in revenue growth could signal a slowdown in the health care sector. This could affect Cardio Diagnostics.
Worry ifSector revenue growth has been below its median for two months in a row.
Less concerning ifSector revenue growth remains at or above its median for two consecutive months.
Why it matters: Securing Medicare coverage is key for broader adoption of their cardiovascular tests. It can drive revenue growth.
Supportive ifLook for news on Medicare coverage or new payment deals for their heart tests.
Worry ifWatch for no new payment deals or delays in Medicare coverage news.
Why it matters: Growing revenue shows that people are using their AI tests. This helps their business.
Supportive ifQ3 2026 revenue exceeds $5.36M, showing strong market traction.
Worry ifIf Q3 2026 revenue is less than $5M, it shows weak market use.
Why it matters: Better clinical validation can build trust and increase use. This is key for success.
Supportive ifLook for new study results that show their tests work well.
Worry ifWatch for no new validation studies or bad results from current studies.
Why it matters: Lower costs can boost profits and help with financial health.
Supportive ifLab COGS reduction exceeds 30% from in-house processing in future quarters.
Worry ifIf lab costs stay above 30% or go up, it shows cost control problems.